Literature DB >> 32860564

Case-Case Comparison of Candida auris Versus Other Candida Species Bloodstream Infections: Results of an Outbreak Investigation in Colombia.

Diego H Caceres1,2, Sandra M Rivera3, Paige A Armstrong4, Patricia Escandon3, Nancy A Chow4, Maria Victoria Ovalle3, Jorge Díaz3, Gordana Derado4, Soraya Salcedo5, Indira Berrio6,7, Andres Espinosa-Bode4, Carmen Varón8, Matthew J Stuckey4, Adriana Mariño9, Nohora Villalobos10, Shawn R Lockhart4, Tom M Chiller4, Franklin E Prieto3, Brendan R Jackson4.   

Abstract

BACKGROUND: Candida auris is an emerging multidrug-resistant yeast that causes outbreaks in healthcare settings around the world. In 2016, clinicians and public health officials identified patients with C. auris bloodstream infections (BSI) in Colombian healthcare facilities. To evaluate potential risk factors and outcomes for these infections, we investigated epidemiologic and clinical features of patients with C. auris and other Candida species BSI.
METHODS: We performed a retrospective case-case investigation in four Colombian acute care hospitals, defining a case as Candida spp. isolated from blood culture during January 2015-September 2016. C. auris BSI cases were compared to other Candida species BSI cases. Odds ratio (OR), estimated using logistic regression, was used to assess the association between risk factors and outcomes.
RESULTS: We analyzed 90 patients with BSI, including 40 with C. auris and 50 with other Candida species. All had been admitted to the intensive care unit (ICU). No significant demographic differences existed between the two groups. The following variables were independently associated with C. auris BSI: ≥ 15 days of pre-infection ICU stay (OR: 5.62, CI: 2.04-15.5), evidence of severe sepsis (OR: 3.70, CI 1.19-11.48), and diabetes mellitus (OR 5.69, CI 1.01-31.9).
CONCLUSION: Patients with C. auris BSI had longer lengths of ICU stay than those with other candidemias, suggesting that infections are acquired during hospitalization. This is different from other Candida infections, which are usually thought to result from autoinfection with host flora.

Entities:  

Keywords:  Candida spp.; Candidemia; Healthcare associated; Outbreak

Mesh:

Substances:

Year:  2020        PMID: 32860564     DOI: 10.1007/s11046-020-00478-1

Source DB:  PubMed          Journal:  Mycopathologia        ISSN: 0301-486X            Impact factor:   2.574


  5 in total

1.  Candida auris Pan-Drug-Resistant to Four Classes of Antifungal Agents.

Authors:  Samantha E Jacobs; Jonathan L Jacobs; Emily K Dennis; Sarah Taimur; Meenakshi Rana; Dhruv Patel; Melissa Gitman; Gopi Patel; Sarah Schaefer; Kishore Iyer; Jang Moon; Victoria Adams; Polina Lerner; Thomas J Walsh; YanChun Zhu; Mohammed Rokebul Anower; Mayuri M Vaidya; Sudha Chaturvedi; Vishnu Chaturvedi
Journal:  Antimicrob Agents Chemother       Date:  2022-06-30       Impact factor: 5.938

2.  Transcriptional Response of Candida auris to the Mrr1 Inducers Methylglyoxal and Benomyl.

Authors:  Amy R Biermann; Deborah A Hogan
Journal:  mSphere       Date:  2022-04-27       Impact factor: 5.029

3.  Detection and Control of Fungal Outbreaks.

Authors:  Diego H Caceres; Ratna Mohd Tap; Ana Alastruey-Izquierdo; Ferry Hagen
Journal:  Mycopathologia       Date:  2020-10-10       Impact factor: 2.574

Review 4.  Invasive Candidiasis: Update and Current Challenges in the Management of This Mycosis in South America.

Authors:  Fernando Oscar Riera; Juan Pablo Caeiro; Sofia Carla Angiolini; Cecilia Vigezzi; Emilse Rodriguez; Paula Alejandra Icely; Claudia Elena Sotomayor
Journal:  Antibiotics (Basel)       Date:  2022-06-30

5.  Novel Environmental Niches for Candida auris: Isolation from a Coastal Habitat in Colombia.

Authors:  Patricia Escandón
Journal:  J Fungi (Basel)       Date:  2022-07-19
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.